EvlaBio
Addressing High Unmet Needs in Cardiorenal Medicine
Switzerland · Founded 2022 · $24.5M raised
- Founded
- 2022
- Business Model
- B2B
- Website
- evlabio.com
- Total Funding
- $24.5M
- Last Round
- $24.5M SeedJul 2025
- Rounds
- 1
About
EvlaBio develops a targeted anti-FGFR4 monoclonal-antibody therapy for people with chronic kidney disease who develop left ventricular hypertrophy. Its mechanism-based program is designed to interrupt the pathological FGF23-FGFR4 signaling pathway while preserving normal FGF23 function, addressing a cardiorenal condition with limited treatment options.
Summary
EvlaBio is a Biotech company based in Switzerland, founded in 2022. It has raised $24.5M in total across 1 round, most recently a $24.5M Seed round in Jul 2025. Investors include Kurma Partners, AdBio Partners and Boehringer Ingelheim Venture Fund.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2025
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/evlabio"><img src="https://indexed.vc/api/badge/company/evlabio" alt="EvlaBio on Indexed.vc" width="260" height="76" /></a>